Commodore Capital LP Acquires Shares of 1,950,000 Karyopharm Therapeutics Inc. $KPTI

Commodore Capital LP acquired a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the first quarter, Holdings Channel reports. The institutional investor acquired 1,950,000 shares of the company’s stock, valued at approximately $10,862,000. Karyopharm Therapeutics makes up approximately 0.6% of Commodore Capital LP’s portfolio, making the stock its 29th largest position. Commodore Capital LP owned about 0.09% of Karyopharm Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KPTI. Corient Private Wealth LLC bought a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $74,000. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics in the second quarter worth about $45,000. Hsbc Holdings PLC bought a new stake in Karyopharm Therapeutics during the first quarter worth approximately $66,000. State Street Corp increased its stake in Karyopharm Therapeutics by 27.2% during the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after acquiring an additional 12,600 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at approximately $95,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock opened at $7.41 on Monday. The stock has a 50 day moving average price of $9.05 and a 200 day moving average price of $8.26. Karyopharm Therapeutics Inc. has a 52-week low of $3.65 and a 52-week high of $10.99. The firm has a market capitalization of $167.93 million, a P/E ratio of -0.49 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to analysts’ expectations of $31.40 million. As a group, sell-side analysts forecast that Karyopharm Therapeutics Inc. will post -3.24 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KPTI shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Tuesday, July 7th. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Thursday, June 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.